摘要
目的:研究仙灵骨松胶囊和福善美(阿仑膦酸钠)防治糖皮质激素(GC)诱发的骨质疏松症(OP)的作用,并对其临床疗效、副作用进行比较。方法:选择需长期服用GC的患者,随机分为治疗组(治疗1组及治疗2组)和预防组(预防1组及预防2组),分别给予仙灵骨松胶囊和福善美口服,观察治疗前后骨密度(BMD)、骨代谢相关指标的变化及副作用等。结果:治疗1组、治疗2组患者治疗后腰椎及股骨近端的骨密度均较治疗前明显提高(P<0.05),血骨钙素(BGP)、尿吡啶啉(U-PYD)/Cr、尿脱氧吡啶啉(U-DPD)/Cr较治疗前显著下降(P<0.05或P<0.01),而血钙、血磷的变化不明显(P>0.05);预防1组、预防2组患者用药后腰椎及股骨近端的骨密度、血BGP均较治疗前有所提高,U-PYD/Cr、U-DPD/Cr有所下降,但差异无显著性(P>0.05),血钙、血磷的变化亦不明显(P>0.05)。结论:两种药物在防治GC所致OP方面均有很好的临床效果,但仙灵骨松胶囊疗效更为显著且副作用小。
Objective ： To observe effect of Xianling Gusong Capsules and Fosamax in prevention and treatment of osteoporosis（OP） induced by glucocorticoid（GC）,and to compare their clinical theraPeutic effects and adverse effects. Methods：The patients needing longterm administration of GC were randomly divided into treatment group Ⅰ , treatment group Ⅱ , prevention group Ⅰ , and prevention group I ,and they were treated with oral administration of Xianling Gusong Capsules and Fosamax ,respectively. Bone mineral density（BMD）,indexes of bone metabolism before and after treatment and adverse effects were investigated. Results：In the two treatment groups,BMD of L2-4 and neck of femur significantly increased（P〈0.05）, and BGP ,urinary pyridinoline （UPYD ）/creatinine （Cr） and urinary deoxy-pyridinoline （U-DPD）/Cr significantly decreased after treatment （P〈0.05 or P〈0. 01）. Blood Ca and P did not have significant change（P〉0.05）. In the prevention groups,after treatment ,BMD of L2-4 and neck of femur, BGP, U-PYD/Cr, U-DPD/Cr, and blood Ca and P levels did not significant changes （P 〉 0. 05）. Conclusion： Both Xianling Gusong Capsules and Fosamax have clinical effects in prevention and treatment of GC-induced osteoporosis, but Xianling Gusong Capsules has more remarkable therapeutic effect and less adverse effects.
出处
《中医杂志》
CSCD
北大核心
2006年第8期596-598,共3页
Journal of Traditional Chinese Medicine
基金
河北省中医药管理局资助项目(05115)
